Newsroom | 40926 results

BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it has successfully amended and extended its $777.5 million Term Loan Facility. The new terms reduce the applicable interest rate by 50 basis points from Term Secured Overnight Financing Rate (SOFR) plus 2.75% to Term SOFR plus 2.25%. The transaction extends the maturity of the facility to September 2032. “This transaction e...

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 182,800 common shares of the Company (the "Options") with effective grant dates of September 15, 2025 and September 22, 2025, depending...

UPPER NYACK, N.Y.--(BUSINESS WIRE)--Global Healthy Living Foundation and Medscape Education Announce Partnership...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, éligible PEA/PME, « Median » ou « La Société »), fabricant d’eyonis®, une suite de logiciels dispositifs médicaux basés sur l’intelligence artificielle (IA) d’aide au diagnostic des cancers, et un leader mondial de la fourniture d’analyses d’images par IA et de services centraux d’imagerie pour les essais cliniques en oncologie de l’industrie biopharmaceutique, fait aujourd’hui un point sur son...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) to aid cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, provides a business update following the successful completion of the financing carried out...

DALLAS--(BUSINESS WIRE)--Sunflower Bank has announced a new partnership with Livestrong, an Austin, TX-based nonprofit organization dedicated to improving the lives of those impacted by cancer. This connection reinforces the bank’s ongoing commitment to the fight against cancer, both in Texas and across its entire footprint, while building on its continued support for cancer awareness initiatives and community health programs. Suzanne Stone, President & CEO of Livestrong reflected on the pa...

LONDON--(BUSINESS WIRE)--International SOS Group Achieves Certification for Excellence in Travel Risk Management...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific™ Hypulse™ Surface Analysis System. This innovative surface analysis instrument represents a leap forward in accurate X-ray photoelectron spectroscopy (XPS) depth-profiling, which is critical for materials scientists around the world. Innovation to Improve Society The Hypulse Surface Analysis System will enable the development of surfaces across industries to impro...

LOS ANGELES--(BUSINESS WIRE)--Salt AI, the leader in contextual AI for enterprise applications in life sciences and health tech, today announced a $10 million funding round, led by Morpheus Ventures, with participation from Struck Capital, Marbruck Investments and CoreWeave. The company will use the capital to expand its customer footprint with leading biopharma and healthcare companies investing in the cutting edge of AI innovation, while also scaling their global AI engineering teams to accel...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced it has completed a new financing round, with gross proceeds of approximately $5.0 million. This financing will fund clinical, non-clinical and CMC activities in anticipation of our plans to initiate an adequate, placebo-controlled Phase 2 clinical study evaluating EVX-101, as adjunctive thera...